Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 9/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490411 | 1.00 | SQOR (0.36) | SQORMAPTTRPV4PDE4APDE4B | |
| SCHEMBL31371842 | 0.84 | TRPV4 (0.37) | SQORMAPTTRPV4PDE4APDE4B | |
| SCHEMBL31432528 | 0.83 | MAPT (0.38) | SQORMAPTTRPV4PDE4APDE4B | |
| SCHEMBL12560589 | 0.79 | MAPT (0.42) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28812390 | 0.79 | TRPV4 (0.42) | TRPV4S1PR1 | |
| SCHEMBL31511101 | 0.78 | TRPV4 (0.38) | SQORTRPV4BRD4 | |
| SCHEMBL25368352 | 0.75 | MAPT (0.42) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22802455 | 0.75 | SQOR (0.33) | SQORBRD4 | |
| SCHEMBL31371917 | 0.75 | TRPV4 (0.38) | MAPTTRPV4S1PR1 | |
| SCHEMBL31432614 | 0.73 | TRPV4 (0.34) | TRPV4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025007873-A1 | KAT6 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2025-01-09 | — | — | WO | disclosed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3986890-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114364672-A | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2022-04-15 | — | — | CN | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | SQOR 14/4885MAPT 4884/4885TRPV4 2910/4885 |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | SQOR 17/4885MAPT 4884/4885TRPV4 2837/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | SQOR 4354/4885MAPT 476/4885TRPV4 4752/4885 |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | SQOR 14/4885MAPT 4884/4885TRPV4 2910/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | SQOR 1304/4885MAPT 1030/4885TRPV4 3638/4885 |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | SQOR 14/4885MAPT 4884/4885TRPV4 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.